EUCTR2006-006626-26-IT进行中（未招募）不适用
A phase III, multicenter, placebo-controlled, double-blind, randomized clinical trial to evaluate the efficacy of bevacizumab in combination with Tarceva (erlotinib) compared with Tarceva alone for treatment of advanced Non Small Cell Lung Cancer (NSCLC) after failure of standard first-Line chemotherapy - ND
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 650
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients must fulfill all of the following criteria to be eligible for study entry: Signed written informed consent Cytologically or histologically confirmed NSCLC Clinical or radiographic progression during or after first-line chemotherapy or chemoradiotherapy for NSCLC Consent to provide archival tissue for analysis is required for participation in this study. Patients who consent to provide tissue but whose archival tissue is found to be inadequate (e.g., stained slides) remain eligible for study participation ECOG performance status of 0, 1, or 2 (see Appendix F) Age >= 18 years
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Patients meeting any of the following criteria will be ineligible for study entry: Squamous cell carcinoma, except for patients with no intrathoracic disease or small peripheral lesions only Prior treatment with an investigational or marketed inhibitor of the EGFR pathway or anti-angiogenesis agent Systemic chemotherapy, radiotherapy, or investigational treatment within 28 days prior to randomization
研究者
相似试验
已完成
3 期
A phase III clinical trial for a novel herbal molecule (1% LLL-2011) developed by Lupin Li,ited which has a potential to prevent attacks of common migraine effectively.CTRI/2009/091/000776upin Limited (Research Park), 46A/47A, Nande village, Mulshi taluka Pune ? 411042, Maharashtra, India214
进行中（未招募）
1 期
A Phase III, Multicenter, Placebo-Controlled, Double-Blind, Randomized Clinical Trial to Evaluate the Efficacy of Bevacizumab in Combination with Tarceva (erlotinib) Compared With Tarceva Alone For Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) After Failure of Standard First-Line Chemotherapyon-small-cell-lung-cancerMedDRA version: 9.1Level: LLTClassification code 10066490Term: Progression of non small cell lung cancerEUCTR2006-006626-26-BEGenentech, Inc.636
进行中（未招募）
不适用
A Phase III, Multicenter, Placebo-Controlled, Double-Blind, Randomized Clinical Trial to Evaluate the Efficacy of Bevacizumab in Combination with Tarceva (erlotinib) Compared With Tarceva Alone For Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) After Failure of Standard First-Line ChemotherapyEUCTR2006-006626-26-DEGenentech, Inc.650
进行中（未招募）
1 期
A Study of Atezolizumab as Monotherapy And in Combination With Platinum-Based Chemotherapy compared to Platinum-Based Chemoteraphy in Patients With Untreated Urothelial CarcinomaEUCTR2016-000250-35-SIF. Hoffmann-La Roche Ltd1,213
进行中（未招募）
1 期
A Study of Atezolizumab as Monotherapy And in Combination With Platinum-Based Chemotherapy compared to Platinum-Based Chemotherapy in Patients With Untreated Urothelial Carcinomarothelial Carcinoma, locally advanced or metastaticMedDRA version: 20.0Level: LLTClassification code 10064467Term: Urothelial carcinomaSystem Organ Class: 100000004864EUCTR2016-000250-35-BEF. Hoffmann-La Roche Ltd1,213